Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis
2007; Elsevier BV; Volume: 31; Issue: 11 Linguagem: Inglês
10.1016/j.leukres.2006.12.025
ISSN1873-5835
AutoresMichelle A. Elliott, Srđan Verstovšek, David Dingli, Susan M. Schwager, Ruben A. Mesa, C. Y. Li, Ayalew Tefferi,
Tópico(s)Eosinophilic Disorders and Syndromes
ResumoWe recently developed a modified Dupriez prognostic scoring system (PSS) that effectively discriminated between high-, intermediate-, and low-risk young patients (age < or =60 years) with primary myelofibrosis (PMF) based on the respective presence of none, one, or two or more of the following parameters: hemoglobin <10 g/dL, leukocyte count 30 x 10(9)L(-1), and platelet count or =1 x 10(9)L(-1) carries an independent predictive value (p=0.02), for an inferior survival, in addition to that provided by hemoglobin level (p=0.002), platelet count (0.02), and leukocyte count (p=0.16). The inclusion of the monocyte count as a fourth risk factor enabled the construction of a new and improved Mayo PSS; median survival was 173, 61, and 26 months in the absence of all four (low-risk), three (intermediate-risk), or two or less (high-risk) adverse features, respectively (p<0.0001). The independent prognostic value of monocytosis was validated in a separate database of 97 patients with PMF from another institution.
Referência(s)